{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:23:30Z","timestamp":1791149010672,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,7,6]],"date-time":"2013-07-06T00:00:00Z","timestamp":1373068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1756-0500-6-254","type":"journal-article","created":{"date-parts":[[2013,7,6]],"date-time":"2013-07-06T12:14:09Z","timestamp":1373112849000},"source":"Crossref","is-referenced-by-count":6,"title":["Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report"],"prefix":"10.1186","volume":"6","author":[{"given":"Kazuo","family":"Ishizuna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwako","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetsugu","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,6]]},"reference":[{"issue":"1","key":"2278_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/GCO.0b013e328334e462","volume":"22","author":"V Bossung","year":"2010","unstructured":"Bossung V, Harbeck N: Angiogenesis inhibitors in the management of breast cancer. Curr Opin Obstet Gynecol. 2010, 22 (1): 79-86. 10.1097\/GCO.0b013e328334e462.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"2","key":"2278_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/BF00666035","volume":"36","author":"N Ferrara","year":"1995","unstructured":"Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat. 1995, 36 (2): 127-137. 10.1007\/BF00666035.","journal-title":"Breast Cancer Res Treat"},{"issue":"6423","key":"2278_CR3","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim KJ, Li B, Winer J, Armanini M, Gillett N, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 1993, 362 (6423): 841-844. 10.1038\/362841a0.","journal-title":"Nature"},{"issue":"2","key":"2278_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nm988","volume":"10","author":"CG Willett","year":"2004","unstructured":"Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004, 10 (2): 145-147. 10.1038\/nm988.","journal-title":"Nat Med"},{"issue":"20","key":"2278_CR5","first-page":"4593","volume":"57","author":"LG Presta","year":"1997","unstructured":"Presta LG, Chen H, O\u2019Connor SJ, Chisholm V, Meng YG, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997, 57 (20): 4593-4599.","journal-title":"Cancer Res"},{"issue":"7","key":"2278_CR6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/CAD.0b013e32833b7598","volume":"21","author":"M Yanagisawa","year":"2010","unstructured":"Yanagisawa M, Yorozu K, Kurasawa M, Nakano K, Furugiki K, et al: Bevacizumab improves the delivery and efficacy of paclitaxel. Anticancer Drugs. 2010, 21 (7): 687-694.","journal-title":"Anticancer Drugs"},{"issue":"26","key":"2278_CR7","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007, 357 (26): 2666-2676. 10.1056\/NEJMoa072113.","journal-title":"N Engl J Med"},{"issue":"20","key":"2278_CR8","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","volume":"28","author":"DW Miles","year":"2010","unstructured":"Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010, 28 (20): 3239-3247. 10.1200\/JCO.2008.21.6457.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2278_CR9","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, et al: RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011, 29 (10): 1252-1260. 10.1200\/JCO.2010.28.0982.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2278_CR10","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.ejca.2008.12.016","volume":"45","author":"KJ Dedes","year":"2009","unstructured":"Dedes KJ, Matter-Walstra K, Schwenkglenks M, Pestolozzi BC, Fink D, et al: Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation. Eur J Cancer. 2009, 45 (8): 1397-1406. 10.1016\/j.ejca.2008.12.016.","journal-title":"Eur J Cancer"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-0500-6-254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-0500-6-254\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-0500-6-254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T14:51:46Z","timestamp":1645973506000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/1756-0500-6-254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,6]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2278"],"URL":"https:\/\/doi.org\/10.1186\/1756-0500-6-254","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,6]]},"article-number":"254"}}